Prescient Holdings Group Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Prescient Holdings Group's estimated annual revenue is currently $9.6M per year.(i)
  • Prescient Holdings Group's estimated revenue per employee is $201,000

Employee Data

  • Prescient Holdings Group has 48 Employees.(i)
  • Prescient Holdings Group grew their employee count by 4% last year.

Prescient Holdings Group's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$84.8M42224%N/AN/A
#2
$0.4M20%N/AN/A
#3
$32M1593%N/AN/A
#4
$35M1213%$62.5MN/A
#5
$30.2M15018%N/AN/A
#6
$135.3M6730%N/AN/A
#7
$110.3M549N/AN/AN/A
#8
$60.1M299-4%N/AN/A
#9
$554.8M17252%N/AN/A
#10
$10.5M524%N/AN/A
Add Company

What Is Prescient Holdings Group?

We think about pharmacy benefits differently. For decades, it has been a widely held view in the industry that the only way to reduce drug costs for consumers is to limit their choices. We say there’s a better way. At PHG, we have brought together industry veterans — clinical, financial, operations, and benefits experts — with a breadth of experience and a shared vision of a future in which prescription benefits are better, simpler, flexible, and affordable. We are uniquely able to do this because of our close working relationships with dozens of pharmaceutical companies and other industry partners, and by thinking differently about pharmacy benefits. What does all of this mean for our clients and consumers? Lower costs, greater choice, and more competition in the marketplace. And while we are recognized for our exceptional ability to help clients fine-tune formularies, we are focused on something greater — a formula for better healthcare.

keywords:N/A

N/A

Total Funding

48

Number of Employees

$9.6M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.4M48-21%N/A
#2
$6.3M484%N/A
#3
$5.6M48-9%N/A
#4
$10.6M48N/AN/A
#5
$15M484%N/A